红运2022的个人主页 - 老虎社区

红运2022

暂无个人介绍

IP属地：湖南

24关注

22粉丝

0主题

0勋章

11:33

$恒指瑞银六五熊Y.P(53860)$ 易经之道。短期恒指有下跌，长期必涨

05-01

模拟盘暴涨12万美金

05-01

感谢特斯拉

04-30

$TSLA 20240517 210.0 CALL$ 模拟盘12万美金一晚。爽一把也行

04-29

感谢特斯拉

04-29

躺挣

04-27

$尚高生命科学(SISI)$ 要起来了

04-25

连续下跌，放量，然后盘前拉一波。这是典型的庄家手法。这个票，要么就是在洗盘猛拉，要么退市。没别的玩法了

04-25

这篇文章不错，转发给大家看看

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

04-25

这篇文章不错，转发给大家看看

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

04-24

坚信特斯拉

04-11

这篇文章不错，转发给大家看看

Is It Too Late To Consider Buying Rent the Runway, Inc. (NASDAQ:RENT)?

04-11

$Rallybio Corp.(RLYB)$ 不清楚他的逻辑

04-10

$Focus Universal, Inc.(FCUV)$ 亏损严重暴跌

04-10

$Vincera Pharma, Inc.(VINC)$ 研发失败，股价暴跌。但是夏季可能研发成功可以潜伏等待

04-08

$MSP Recovery, Inc.(LIFW)$ 卖飞了

04-08

$Longeveron Inc(LGVN)$ 两张图看蹊跷

04-08

$联代科技(WTO)$ 盘前猛涨，3号流入为正，股价为负，反常

04-08

$瑞图生态(RETO)$ 神经一样的股票，盘前先是拉到50个点，然后死跌，莫名其妙

04-04

$Keyarch Acquisition Corp(KYCH)$ 完美逃过一劫

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4118205146243860,"uuid":"4118205146243860","gmtCreate":1655102066845,"gmtModify":1655102066845,"name":"红运2022","pinyin":"hy2022hongyun2022","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":22,"headSize":24,"tweetSize":123,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":8,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.22","exceedPercentage":"93.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.03","exceedPercentage":"93.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"湖南","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":302941501505600,"gmtCreate":1714966408928,"gmtModify":1714966412688,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/53860\">$恒指瑞银六五熊Y.P(53860)$ &nbsp;</a> 易经之道。短期恒指有下跌，长期必涨","listText":"<a href=\"https://laohu8.com/S/53860\">$恒指瑞银六五熊Y.P(53860)$ &nbsp;</a> 易经之道。短期恒指有下跌，长期必涨","text":"$恒指瑞银六五熊Y.P(53860)$ 易经之道。短期恒指有下跌，长期必涨","images":[{"img":"https://static.tigerbbs.com/0e55b977d567c089546ff2cb88f9d88e","width":"906","height":"1406"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/302941501505600","isVote":1,"tweetType":1,"viewCount":65,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":301037796114680,"gmtCreate":1714501641586,"gmtModify":1714501709111,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"模拟盘暴涨12万美金","listText":"模拟盘暴涨12万美金","text":"模拟盘暴涨12万美金","images":[{"img":"https://static.tigerbbs.com/49a585851bcce2fc54ac76824b8a1931","width":"1002","height":"1095"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/301037796114680","isVote":1,"tweetType":1,"viewCount":14,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":301029337063736,"gmtCreate":1714499712381,"gmtModify":1714500895846,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"感谢特斯拉","listText":"感谢特斯拉","text":"感谢特斯拉","images":[{"img":"https://static.tigerbbs.com/d999684aee27b7d2370a00c09f73b35d","width":"1002","height":"1154"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/301029337063736","isVote":1,"tweetType":1,"viewCount":32,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":300618599141688,"gmtCreate":1714412684257,"gmtModify":1714412688388,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/OPT/TSLA 20240517 210.0 CALL\">$TSLA 20240517 210.0 CALL$ &nbsp;</a>模拟盘12万美金一晚。爽一把也行","listText":"<a href=\"https://laohu8.com/OPT/TSLA 20240517 210.0 CALL\">$TSLA 20240517 210.0 CALL$ &nbsp;</a>模拟盘12万美金一晚。爽一把也行","text":"$TSLA 20240517 210.0 CALL$ 模拟盘12万美金一晚。爽一把也行","images":[{"img":"https://static.tigerbbs.com/92f4f1a3cfc0e930b5796f3e00c766b2","width":"906","height":"1406"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/300618599141688","isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":300552513052960,"gmtCreate":1714396590280,"gmtModify":1714396595388,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"感谢特斯拉","listText":"感谢特斯拉","text":"感谢特斯拉","images":[{"img":"https://static.tigerbbs.com/8914cdac1b2858666d3b5c7d8122f512","width":"906","height":"1406"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/300552513052960","isVote":1,"tweetType":1,"viewCount":105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":300545213018312,"gmtCreate":1714394693110,"gmtModify":1714394702135,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"躺挣","listText":"躺挣","text":"躺挣","images":[{"img":"https://static.tigerbbs.com/9cd78e4d8747cf12465c73da862495c5","width":"1080","height":"2400"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/300545213018312","isVote":1,"tweetType":1,"viewCount":38,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":299545608568888,"gmtCreate":1714150648467,"gmtModify":1714150649827,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SISI\">$尚高生命科学(SISI)$ &nbsp;</a>要起来了","listText":"<a href=\"https://laohu8.com/S/SISI\">$尚高生命科学(SISI)$ &nbsp;</a>要起来了","text":"$尚高生命科学(SISI)$ 要起来了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/299545608568888","isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":299145321619504,"gmtCreate":1714058810832,"gmtModify":1714058813049,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"连续下跌，放量，然后盘前拉一波。这是典型的庄家手法。 这个票，要么就是在洗盘猛拉，要么退市。没别的玩法了","listText":"连续下跌，放量，然后盘前拉一波。这是典型的庄家手法。 这个票，要么就是在洗盘猛拉，要么退市。没别的玩法了","text":"连续下跌，放量，然后盘前拉一波。这是典型的庄家手法。 这个票，要么就是在洗盘猛拉，要么退市。没别的玩法了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/299145321619504","isVote":1,"tweetType":1,"viewCount":40,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":298796179763384,"gmtCreate":1713977561744,"gmtModify":1713977563111,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/298796179763384","repostId":"2429480258","repostType":2,"repost":{"id":"2429480258","pubTimestamp":1713952200,"share":"https://www.laohu8.com/m/news/2429480258?lang=&edition=full","pubTime":"2024-04-24 17:50","market":"fut","language":"en","title":"Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.","url":"https://stock-news.laohu8.com/highlight/detail?id=2429480258","media":"Motley Fool","summary":"Good news could be just around the corner for two drugmakers not named Novo Nordisk.","content":"<html><body><ul>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.</div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Vertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.</div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has key potential catalysts coming soon for its promising NASH and X-ALD therapies.</div>\n</li>\n</ul><div><p>Ozempic and Wegovy are the rock stars of the biopharmaceutical world. When celebrities talk about a prescription drug, it has reached the big time. And that's what has happened with <strong>Novo Nordisk</strong>'s two blockbusters<strong>. </strong></p><p>The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big drugmaker have skyrocketed nearly 240% over the last three years.</p><p>Don't worry if you think you've missed out on Novo Nordisk, though. Here are two healthcare stocks with big catalysts on the horizon.</p><h2>1. Vertex Pharmaceuticals</h2><p><strong>Vertex Pharmaceuticals</strong> <span>(VRTX<span> 1.25%</span>)</span> doesn't have celebrities name-dropping its products, but it has achieved tremendous success. The big biotech markets the only therapies that treat the underlying cause of cystic fibrosis (CF). Vertex, along with its partner <strong>CRISPR Therapeutics</strong>, also now has the first (and so far only) CRISPR gene-editing therapy on the market.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"206020\" :show_benchmark_compare=\"false\" amount_change=\"4.99\" average_volume=\"1,219,252\" company_name=\"Vertex Pharmaceuticals\" current_price=\"404.91\" daily_high=\"406.86\" daily_low=\"403.47\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"448.40\" fifty_two_week_low=\"316.43\" gross_margin=\"87.17\" logo=\"https://g.foolcdn.com/art/companylogos/mark/VRTX.png\" market_cap=\"$105B\" pe_ratio=\"29.15\" percent_change=\"1.25\" symbol=\"VRTX\" volume=\"5\"></app></div><p>We might not have to wait long for Vertex to add to its success story. The company has already submitted the first module to the U.S. Food and Drug Administration (FDA) in a rolling submission for suzetrigine (formerly known as VX-548) in treating acute pain. Vertex expects to complete the full filing by the end of the second quarter of 2024.</p><div><div></div></div><p>Acute pain represents a multibillion-dollar market dominated by anti-inflammatory drugs that are safe but have limited efficacy and opioids that are effective but have a high potential for addiction. Suzetrigine uses a novel method of alleviating pain (inhibiting a pain signal inhibitor called NaV1.8) that's effective and safe without addictive qualities. </p><p>Vertex also has another regulatory filing on the way this summer for its vanzacaftor/tezacaftor/deutivacaftor combination therapy targeting CF. This triple-drug combo was as good as or better than the company's top-selling CF drug, Trikafta, in phase 3 testing. Because of the vanzacaftor therapy's convenient once-daily dosing and its significantly lower royalty burden, I expect it will become Vertex's most profitable CF therapy yet if approved. </p><h2>2. Viking Therapeutics</h2><p>If you want a big opportunity in the obesity market along the lines of what Novo Nordisk has experienced, <strong>Viking Therapeutics</strong> <span>(VKTX<span> 1.69%</span>)</span> could be a great pick for you. And Viking's obesity drugs just might be better than Novo's Wegovy.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"335108\" :show_benchmark_compare=\"false\" amount_change=\"1.08\" average_volume=\"6,400,240\" company_name=\"Viking Therapeutics\" current_price=\"64.93\" daily_high=\"67.58\" daily_low=\"63.51\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"99.41\" fifty_two_week_low=\"8.28\" gross_margin=\"0.00\" logo=\"https://g.foolcdn.com/art/companylogos/mark/VKTX.png\" market_cap=\"$7B\" pe_ratio=\"-70.97\" percent_change=\"1.69\" symbol=\"VKTX\" volume=\"496\"></app></div><p>In February, Viking announced overwhelmingly positive results from a phase 2 study of VK2735. Patients receiving the experimental drug achieved up to 13.1% placebo-adjusted mean weight loss after 13 weeks of treatment. These results were more impressive than those seen in the clinical trials of Wegovy and <strong>Eli Lill</strong>y's Zepbound. </p><div><div></div></div><p>One month later, Viking reported more good news for VK2735. This time it was with an oral version of the weight-loss drug. The company announced positive results from a phase 1 study. Perhaps most encouraging was the oral formulation of VK2735 had low rates of gastrointestinal-related side effects. </p><p>But the next big catalyst for Viking could come from other pipeline candidates. The clinical-stage biotech expects to announce histology results from a phase 1 study evaluating VK2809 in treating nonalcoholic steatohepatitis (NASH) and fibrosis by mid-2024. It also should report results from a phase 1b study of VK0214 in treating rare neurodegenerative disease X-linked adrenoleukodystrophy (X-ALD). </p><div></div></div></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-24 17:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.\n\n\n\n\n\n\n\nVertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.\n\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773900%2Fyoung-woman-frustrated-laptop.jpg&op=resize&w=165&h=104","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0079474960.USD":"联博美国增长基金A","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4093":"化肥与农用药剂","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","CF":"CF工业","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","HCSG":"医疗保健服务","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4137":"综合支持服务","LU0058720904.USD":"联博国际健康护理基金A","BK4023":"应用软件","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4532":"文艺复兴科技持仓","VERX":"Vertex, Inc.","VRTX":"福泰制药","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","NVO":"诺和诺德","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"source_url":"https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2429480258","content_text":"Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.\n\n\n\n\n\n\n\nVertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.\n\n\n\n\n\n\n\nViking Therapeutics has key potential catalysts coming soon for its promising NASH and X-ALD therapies.\n\nOzempic and Wegovy are the rock stars of the biopharmaceutical world. When celebrities talk about a prescription drug, it has reached the big time. And that's what has happened with Novo Nordisk's two blockbusters. The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big drugmaker have skyrocketed nearly 240% over the last three years.Don't worry if you think you've missed out on Novo Nordisk, though. Here are two healthcare stocks with big catalysts on the horizon.1. Vertex PharmaceuticalsVertex Pharmaceuticals (VRTX 1.25%) doesn't have celebrities name-dropping its products, but it has achieved tremendous success. The big biotech markets the only therapies that treat the underlying cause of cystic fibrosis (CF). Vertex, along with its partner CRISPR Therapeutics, also now has the first (and so far only) CRISPR gene-editing therapy on the market.We might not have to wait long for Vertex to add to its success story. The company has already submitted the first module to the U.S. Food and Drug Administration (FDA) in a rolling submission for suzetrigine (formerly known as VX-548) in treating acute pain. Vertex expects to complete the full filing by the end of the second quarter of 2024.Acute pain represents a multibillion-dollar market dominated by anti-inflammatory drugs that are safe but have limited efficacy and opioids that are effective but have a high potential for addiction. Suzetrigine uses a novel method of alleviating pain (inhibiting a pain signal inhibitor called NaV1.8) that's effective and safe without addictive qualities. Vertex also has another regulatory filing on the way this summer for its vanzacaftor/tezacaftor/deutivacaftor combination therapy targeting CF. This triple-drug combo was as good as or better than the company's top-selling CF drug, Trikafta, in phase 3 testing. Because of the vanzacaftor therapy's convenient once-daily dosing and its significantly lower royalty burden, I expect it will become Vertex's most profitable CF therapy yet if approved. 2. Viking TherapeuticsIf you want a big opportunity in the obesity market along the lines of what Novo Nordisk has experienced, Viking Therapeutics (VKTX 1.69%) could be a great pick for you. And Viking's obesity drugs just might be better than Novo's Wegovy.In February, Viking announced overwhelmingly positive results from a phase 2 study of VK2735. Patients receiving the experimental drug achieved up to 13.1% placebo-adjusted mean weight loss after 13 weeks of treatment. These results were more impressive than those seen in the clinical trials of Wegovy and Eli Lilly's Zepbound. One month later, Viking reported more good news for VK2735. This time it was with an oral version of the weight-loss drug. The company announced positive results from a phase 1 study. Perhaps most encouraging was the oral formulation of VK2735 had low rates of gastrointestinal-related side effects. But the next big catalyst for Viking could come from other pipeline candidates. The clinical-stage biotech expects to announce histology results from a phase 1 study evaluating VK2809 in treating nonalcoholic steatohepatitis (NASH) and fibrosis by mid-2024. It also should report results from a phase 1b study of VK0214 in treating rare neurodegenerative disease X-linked adrenoleukodystrophy (X-ALD).","news_type":1},"isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":298796162846720,"gmtCreate":1713977556818,"gmtModify":1713977558537,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/298796162846720","repostId":"2429480258","repostType":2,"repost":{"id":"2429480258","pubTimestamp":1713952200,"share":"https://www.laohu8.com/m/news/2429480258?lang=&edition=full","pubTime":"2024-04-24 17:50","market":"fut","language":"en","title":"Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.","url":"https://stock-news.laohu8.com/highlight/detail?id=2429480258","media":"Motley Fool","summary":"Good news could be just around the corner for two drugmakers not named Novo Nordisk.","content":"<html><body><ul>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.</div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Vertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.</div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has key potential catalysts coming soon for its promising NASH and X-ALD therapies.</div>\n</li>\n</ul><div><p>Ozempic and Wegovy are the rock stars of the biopharmaceutical world. When celebrities talk about a prescription drug, it has reached the big time. And that's what has happened with <strong>Novo Nordisk</strong>'s two blockbusters<strong>. </strong></p><p>The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big drugmaker have skyrocketed nearly 240% over the last three years.</p><p>Don't worry if you think you've missed out on Novo Nordisk, though. Here are two healthcare stocks with big catalysts on the horizon.</p><h2>1. Vertex Pharmaceuticals</h2><p><strong>Vertex Pharmaceuticals</strong> <span>(VRTX<span> 1.25%</span>)</span> doesn't have celebrities name-dropping its products, but it has achieved tremendous success. The big biotech markets the only therapies that treat the underlying cause of cystic fibrosis (CF). Vertex, along with its partner <strong>CRISPR Therapeutics</strong>, also now has the first (and so far only) CRISPR gene-editing therapy on the market.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"206020\" :show_benchmark_compare=\"false\" amount_change=\"4.99\" average_volume=\"1,219,252\" company_name=\"Vertex Pharmaceuticals\" current_price=\"404.91\" daily_high=\"406.86\" daily_low=\"403.47\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"448.40\" fifty_two_week_low=\"316.43\" gross_margin=\"87.17\" logo=\"https://g.foolcdn.com/art/companylogos/mark/VRTX.png\" market_cap=\"$105B\" pe_ratio=\"29.15\" percent_change=\"1.25\" symbol=\"VRTX\" volume=\"5\"></app></div><p>We might not have to wait long for Vertex to add to its success story. The company has already submitted the first module to the U.S. Food and Drug Administration (FDA) in a rolling submission for suzetrigine (formerly known as VX-548) in treating acute pain. Vertex expects to complete the full filing by the end of the second quarter of 2024.</p><div><div></div></div><p>Acute pain represents a multibillion-dollar market dominated by anti-inflammatory drugs that are safe but have limited efficacy and opioids that are effective but have a high potential for addiction. Suzetrigine uses a novel method of alleviating pain (inhibiting a pain signal inhibitor called NaV1.8) that's effective and safe without addictive qualities. </p><p>Vertex also has another regulatory filing on the way this summer for its vanzacaftor/tezacaftor/deutivacaftor combination therapy targeting CF. This triple-drug combo was as good as or better than the company's top-selling CF drug, Trikafta, in phase 3 testing. Because of the vanzacaftor therapy's convenient once-daily dosing and its significantly lower royalty burden, I expect it will become Vertex's most profitable CF therapy yet if approved. </p><h2>2. Viking Therapeutics</h2><p>If you want a big opportunity in the obesity market along the lines of what Novo Nordisk has experienced, <strong>Viking Therapeutics</strong> <span>(VKTX<span> 1.69%</span>)</span> could be a great pick for you. And Viking's obesity drugs just might be better than Novo's Wegovy.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"335108\" :show_benchmark_compare=\"false\" amount_change=\"1.08\" average_volume=\"6,400,240\" company_name=\"Viking Therapeutics\" current_price=\"64.93\" daily_high=\"67.58\" daily_low=\"63.51\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"99.41\" fifty_two_week_low=\"8.28\" gross_margin=\"0.00\" logo=\"https://g.foolcdn.com/art/companylogos/mark/VKTX.png\" market_cap=\"$7B\" pe_ratio=\"-70.97\" percent_change=\"1.69\" symbol=\"VKTX\" volume=\"496\"></app></div><p>In February, Viking announced overwhelmingly positive results from a phase 2 study of VK2735. Patients receiving the experimental drug achieved up to 13.1% placebo-adjusted mean weight loss after 13 weeks of treatment. These results were more impressive than those seen in the clinical trials of Wegovy and <strong>Eli Lill</strong>y's Zepbound. </p><div><div></div></div><p>One month later, Viking reported more good news for VK2735. This time it was with an oral version of the weight-loss drug. The company announced positive results from a phase 1 study. Perhaps most encouraging was the oral formulation of VK2735 had low rates of gastrointestinal-related side effects. </p><p>But the next big catalyst for Viking could come from other pipeline candidates. The clinical-stage biotech expects to announce histology results from a phase 1 study evaluating VK2809 in treating nonalcoholic steatohepatitis (NASH) and fibrosis by mid-2024. It also should report results from a phase 1b study of VK0214 in treating rare neurodegenerative disease X-linked adrenoleukodystrophy (X-ALD). </p><div></div></div></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-24 17:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.\n\n\n\n\n\n\n\nVertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.\n\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773900%2Fyoung-woman-frustrated-laptop.jpg&op=resize&w=165&h=104","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0079474960.USD":"联博美国增长基金A","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4093":"化肥与农用药剂","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","CF":"CF工业","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","HCSG":"医疗保健服务","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4137":"综合支持服务","LU0058720904.USD":"联博国际健康护理基金A","BK4023":"应用软件","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4532":"文艺复兴科技持仓","VERX":"Vertex, Inc.","VRTX":"福泰制药","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","NVO":"诺和诺德","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"source_url":"https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2429480258","content_text":"Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.\n\n\n\n\n\n\n\nVertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.\n\n\n\n\n\n\n\nViking Therapeutics has key potential catalysts coming soon for its promising NASH and X-ALD therapies.\n\nOzempic and Wegovy are the rock stars of the biopharmaceutical world. When celebrities talk about a prescription drug, it has reached the big time. And that's what has happened with Novo Nordisk's two blockbusters. The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big drugmaker have skyrocketed nearly 240% over the last three years.Don't worry if you think you've missed out on Novo Nordisk, though. Here are two healthcare stocks with big catalysts on the horizon.1. Vertex PharmaceuticalsVertex Pharmaceuticals (VRTX 1.25%) doesn't have celebrities name-dropping its products, but it has achieved tremendous success. The big biotech markets the only therapies that treat the underlying cause of cystic fibrosis (CF). Vertex, along with its partner CRISPR Therapeutics, also now has the first (and so far only) CRISPR gene-editing therapy on the market.We might not have to wait long for Vertex to add to its success story. The company has already submitted the first module to the U.S. Food and Drug Administration (FDA) in a rolling submission for suzetrigine (formerly known as VX-548) in treating acute pain. Vertex expects to complete the full filing by the end of the second quarter of 2024.Acute pain represents a multibillion-dollar market dominated by anti-inflammatory drugs that are safe but have limited efficacy and opioids that are effective but have a high potential for addiction. Suzetrigine uses a novel method of alleviating pain (inhibiting a pain signal inhibitor called NaV1.8) that's effective and safe without addictive qualities. Vertex also has another regulatory filing on the way this summer for its vanzacaftor/tezacaftor/deutivacaftor combination therapy targeting CF. This triple-drug combo was as good as or better than the company's top-selling CF drug, Trikafta, in phase 3 testing. Because of the vanzacaftor therapy's convenient once-daily dosing and its significantly lower royalty burden, I expect it will become Vertex's most profitable CF therapy yet if approved. 2. Viking TherapeuticsIf you want a big opportunity in the obesity market along the lines of what Novo Nordisk has experienced, Viking Therapeutics (VKTX 1.69%) could be a great pick for you. And Viking's obesity drugs just might be better than Novo's Wegovy.In February, Viking announced overwhelmingly positive results from a phase 2 study of VK2735. Patients receiving the experimental drug achieved up to 13.1% placebo-adjusted mean weight loss after 13 weeks of treatment. These results were more impressive than those seen in the clinical trials of Wegovy and Eli Lilly's Zepbound. One month later, Viking reported more good news for VK2735. This time it was with an oral version of the weight-loss drug. The company announced positive results from a phase 1 study. Perhaps most encouraging was the oral formulation of VK2735 had low rates of gastrointestinal-related side effects. But the next big catalyst for Viking could come from other pipeline candidates. The clinical-stage biotech expects to announce histology results from a phase 1 study evaluating VK2809 in treating nonalcoholic steatohepatitis (NASH) and fibrosis by mid-2024. It also should report results from a phase 1b study of VK0214 in treating rare neurodegenerative disease X-linked adrenoleukodystrophy (X-ALD).","news_type":1},"isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":298545034559672,"gmtCreate":1713919464020,"gmtModify":1713919469446,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"坚信特斯拉","listText":"坚信特斯拉","text":"坚信特斯拉","images":[{"img":"https://static.tigerbbs.com/059790797bba685d52792b2cde0e37d8","width":"906","height":"1406"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/298545034559672","isVote":1,"tweetType":1,"viewCount":49,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":294115591827752,"gmtCreate":1712828588835,"gmtModify":1712828590349,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/294115591827752","repostId":"2424349396","repostType":2,"repost":{"id":"2424349396","pubTimestamp":1712231430,"share":"https://www.laohu8.com/m/news/2424349396?lang=&edition=full","pubTime":"2024-04-04 19:50","market":"us","language":"en","title":"Is It Too Late To Consider Buying Rent the Runway, Inc. (NASDAQ:RENT)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2424349396","media":"Simply Wall St.","summary":"Rent the Runway, Inc. , is not the largest company out there, but it received a lot of attention from a substantial price movement on the NASDAQCM over the last few months, increasing to US$14.69 at one point, and dropping to the lows of US$5.88. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Rent the Runway's current trading price of US$5.88 reflective of the actual value of the small-cap?Or is it currently undervalued, providing us with the opportunity to buy?Let’s take a look at Rent the Runway’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.","content":"<html><body><p><a href=\"https://laohu8.com/S/RENT\">Rent the Runway, Inc.</a> (NASDAQ:RENT), is not the largest company out there, but it received a lot of attention from a substantial price movement on the NASDAQCM over the last few months, increasing to US$14.69 at one point, and dropping to the lows of US$5.88. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Rent the Runway's current trading price of US$5.88 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Rent the Runway’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. </p>\n<p><span> Check out our latest analysis for Rent the Runway </span></p>\n<h2> Is Rent the Runway Still Cheap? </h2>\n<p> Great news for investors – Rent the Runway is still trading at a fairly cheap price. According to our valuation, the intrinsic value for the stock is $9.20, but it is currently trading at US$5.88 on the share market, meaning that there is still an opportunity to buy now. Another thing to keep in mind is that Rent the Runway’s share price may be quite stable relative to the rest of the market, as indicated by its low beta. This means that if you believe the current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range again. </p>\n<h2> Can we expect growth from Rent the Runway? </h2>\n<figure>\n<img height=\"524\" src=\"https://s.yimg.com/uu/api/res/1.2/BG_bancIefqx8l2fNaAAuA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/simply_wall_st__316/b5f91f30b0bea9b0a0b2fdace548bba9\" width=\"821\"/>\n<figcaption>\n  NasdaqCM:RENT Earnings and Revenue Growth April 4th 2024\n </figcaption>\n</figure>\n<p> Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Rent the Runway's earnings over the next few years are expected to increase by 27%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. </p>\n<h2>What This Means For You</h2>\n<p><strong>Are you a shareholder?</strong> Since RENT is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation. </p>\n<p><strong>Are you a potential investor?</strong> If you’ve been keeping an eye on RENT for a while, now might be the time to make a leap. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy RENT. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy. </p>\n<p> If you'd like to know more about Rent the Runway as a business, it's important to be aware of any risks it's facing. To help with this, we've discovered <strong>5 warning signs</strong> (1 can't be ignored!) that you ought to be aware of before buying any shares in Rent the Runway. </p>\n<p> If you are no longer interested in Rent the Runway, you can use our free platform to see our list of over 50 other stocks with a high growth potential. </p>\n<p><strong>Have feedback on this article? Concerned about the content?</strong> <strong>Get in touch</strong><strong> with us directly.</strong><i> Alternatively, email editorial-team (at) simplywallst.com.</i><br/><br/><i>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</i><br/><br/></p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Buying Rent the Runway, Inc. (NASDAQ:RENT)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Buying Rent the Runway, Inc. (NASDAQ:RENT)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-04 19:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/too-consider-buying-rent-runway-115030454.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rent the Runway, Inc. (NASDAQ:RENT), is not the largest company out there, but it received a lot of attention from a substantial price movement on the NASDAQCM over the last few months, increasing to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/too-consider-buying-rent-runway-115030454.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/D5RQ4IawidDVtnEYQELG0g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/bba80cef4667ee8433810d7fbee032a7","relate_stocks":{"SQQQ":"纳指三倍做空ETF","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","QID":"纳指两倍做空ETF","NDAQ":"纳斯达克OMX交易所","QQQ":"纳指100ETF",".IXIC":"NASDAQ Composite","QLD":"纳指两倍做多ETF","BK4588":"碎股","BK4122":"互联网与直销零售","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4200":"专卖店","BK4112":"金融交易所和数据","PSQ":"纳指反向ETF","RENT":"Rent the Runway, Inc.","TQQQ":"纳指三倍做多ETF"},"source_url":"https://finance.yahoo.com/news/too-consider-buying-rent-runway-115030454.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2424349396","content_text":"Rent the Runway, Inc. (NASDAQ:RENT), is not the largest company out there, but it received a lot of attention from a substantial price movement on the NASDAQCM over the last few months, increasing to US$14.69 at one point, and dropping to the lows of US$5.88. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Rent the Runway's current trading price of US$5.88 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Rent the Runway’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. \n Check out our latest analysis for Rent the Runway \n Is Rent the Runway Still Cheap? \n Great news for investors – Rent the Runway is still trading at a fairly cheap price. According to our valuation, the intrinsic value for the stock is $9.20, but it is currently trading at US$5.88 on the share market, meaning that there is still an opportunity to buy now. Another thing to keep in mind is that Rent the Runway’s share price may be quite stable relative to the rest of the market, as indicated by its low beta. This means that if you believe the current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range again. \n Can we expect growth from Rent the Runway? \n\n\n\n  NasdaqCM:RENT Earnings and Revenue Growth April 4th 2024\n \n\n Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Rent the Runway's earnings over the next few years are expected to increase by 27%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. \nWhat This Means For You\nAre you a shareholder? Since RENT is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation. \nAre you a potential investor? If you’ve been keeping an eye on RENT for a while, now might be the time to make a leap. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy RENT. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy. \n If you'd like to know more about Rent the Runway as a business, it's important to be aware of any risks it's facing. To help with this, we've discovered 5 warning signs (1 can't be ignored!) that you ought to be aware of before buying any shares in Rent the Runway. \n If you are no longer interested in Rent the Runway, you can use our free platform to see our list of over 50 other stocks with a high growth potential. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","news_type":1},"isVote":1,"tweetType":1,"viewCount":88,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":294113814380760,"gmtCreate":1712828298238,"gmtModify":1712828303115,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RLYB\">$Rallybio Corp.(RLYB)$ &nbsp;</a>不清楚他的逻辑","listText":"<a href=\"https://laohu8.com/S/RLYB\">$Rallybio Corp.(RLYB)$ &nbsp;</a>不清楚他的逻辑","text":"$Rallybio Corp.(RLYB)$ 不清楚他的逻辑","images":[{"img":"https://static.tigerbbs.com/d32ba1ad959f1e88564e5bb102362921","width":"1080","height":"2591"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/294113814380760","isVote":1,"tweetType":1,"viewCount":185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":293520628617432,"gmtCreate":1712679944649,"gmtModify":1712681293687,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FCUV\">$Focus Universal, Inc.(FCUV)$ &nbsp;</a>亏损严重暴跌","listText":"<a href=\"https://laohu8.com/S/FCUV\">$Focus Universal, Inc.(FCUV)$ &nbsp;</a>亏损严重暴跌","text":"$Focus Universal, Inc.(FCUV)$ 亏损严重暴跌","images":[{"img":"https://static.tigerbbs.com/fa0df7a38f087cd6684b3f0cbb46d017","width":"1080","height":"2400"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/293520628617432","isVote":1,"tweetType":1,"viewCount":120,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":293520517881872,"gmtCreate":1712679875588,"gmtModify":1712679880816,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VINC\">$Vincera Pharma, Inc.(VINC)$ &nbsp;</a>研发失败，股价暴跌。 但是夏季可能研发成功可以潜伏等待","listText":"<a href=\"https://laohu8.com/S/VINC\">$Vincera Pharma, Inc.(VINC)$ &nbsp;</a>研发失败，股价暴跌。 但是夏季可能研发成功可以潜伏等待","text":"$Vincera Pharma, Inc.(VINC)$ 研发失败，股价暴跌。 但是夏季可能研发成功可以潜伏等待","images":[{"img":"https://static.tigerbbs.com/100b1a5b4b112bea5ce0ada4f70d90bf","width":"1080","height":"2400"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/293520517881872","isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":293135769026760,"gmtCreate":1712585881024,"gmtModify":1712585882113,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LIFW\">$MSP Recovery, Inc.(LIFW)$ &nbsp;</a>卖飞了","listText":"<a href=\"https://laohu8.com/S/LIFW\">$MSP Recovery, Inc.(LIFW)$ &nbsp;</a>卖飞了","text":"$MSP Recovery, Inc.(LIFW)$ 卖飞了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/293135769026760","isVote":1,"tweetType":1,"viewCount":191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":293100978790568,"gmtCreate":1712577476473,"gmtModify":1712577486171,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LGVN\">$Longeveron Inc(LGVN)$ &nbsp;</a>两张图看蹊跷","listText":"<a href=\"https://laohu8.com/S/LGVN\">$Longeveron Inc(LGVN)$ &nbsp;</a>两张图看蹊跷","text":"$Longeveron Inc(LGVN)$ 两张图看蹊跷","images":[{"img":"https://static.tigerbbs.com/37442b679b0b3bdd7d42676b7b8997f7","width":"1080","height":"2400"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/293100978790568","isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},{"id":293100527898704,"gmtCreate":1712577374576,"gmtModify":1712577379951,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WTO\">$联代科技(WTO)$ &nbsp;</a>盘前猛涨，3号流入为正，股价为负，反常","listText":"<a href=\"https://laohu8.com/S/WTO\">$联代科技(WTO)$ &nbsp;</a>盘前猛涨，3号流入为正，股价为负，反常","text":"$联代科技(WTO)$ 盘前猛涨，3号流入为正，股价为负，反常","images":[{"img":"https://static.tigerbbs.com/0f207f7d4fe7b433e9bd1a69a478d560","width":"1080","height":"2400"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/293100527898704","isVote":1,"tweetType":1,"viewCount":317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":293099879219208,"gmtCreate":1712577234229,"gmtModify":1712582616022,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RETO\">$瑞图生态(RETO)$ &nbsp;</a> 神经一样的股票，盘前先是拉到50个点，然后死跌，莫名其妙","listText":"<a href=\"https://laohu8.com/S/RETO\">$瑞图生态(RETO)$ &nbsp;</a> 神经一样的股票，盘前先是拉到50个点，然后死跌，莫名其妙","text":"$瑞图生态(RETO)$ 神经一样的股票，盘前先是拉到50个点，然后死跌，莫名其妙","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/293099879219208","isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":291703867961552,"gmtCreate":1712242653098,"gmtModify":1712242657894,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/KYCH\">$Keyarch Acquisition Corp(KYCH)$ &nbsp;</a> 完美逃过一劫","listText":"<a href=\"https://laohu8.com/S/KYCH\">$Keyarch Acquisition Corp(KYCH)$ &nbsp;</a> 完美逃过一劫","text":"$Keyarch Acquisition Corp(KYCH)$ 完美逃过一劫","images":[{"img":"https://static.tigerbbs.com/cf6f72414384a46ceb424e64d6f6302e","width":"1080","height":"2591"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/291703867961552","isVote":1,"tweetType":1,"viewCount":134,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":629585246,"gmtCreate":1670602482486,"gmtModify":1670605489885,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ &nbsp;</a>法拉第未来适合赌博。有点闲钱的，赌进去。比如，扔个W的人民币也好，或者扔个W的美元也罢。 放着，别管。 如果一年后没了，也就是1个w没了。一旦，他起来了，那就是几十倍的翻。 所以，我赌了把，放了7000美金。 如果输了我也认。","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ &nbsp;</a>法拉第未来适合赌博。有点闲钱的，赌进去。比如，扔个W的人民币也好，或者扔个W的美元也罢。 放着，别管。 如果一年后没了，也就是1个w没了。一旦，他起来了，那就是几十倍的翻。 所以，我赌了把，放了7000美金。 如果输了我也认。","text":"$Faraday Future(FFIE)$ 法拉第未来适合赌博。有点闲钱的，赌进去。比如，扔个W的人民币也好，或者扔个W的美元也罢。 放着，别管。 如果一年后没了，也就是1个w没了。一旦，他起来了，那就是几十倍的翻。 所以，我赌了把，放了7000美金。 如果输了我也认。","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":98,"commentSize":15,"repostSize":4,"link":"https://laohu8.com/post/629585246","isVote":1,"tweetType":1,"viewCount":16144,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"227551038852195","authorId":"227551038852195","name":"长浦资本","avatar":"https://static.laohu8.com/145cb5075a93bae21d969f8831d4d94d","crmLevel":5,"crmLevelSwitch":0},"content":"如果有一点价值的股当然值得这么赌，但像这种老千股背后资本是毫无底线的，它可以一直增发 一直合股 一直跌，最后你会发现哪怕涨百倍，你也回不了本！","text":"如果有一点价值的股当然值得这么赌，但像这种老千股背后资本是毫无底线的，它可以一直增发 一直合股 一直跌，最后你会发现哪怕涨百倍，你也回不了本！","html":"如果有一点价值的股当然值得这么赌，但像这种老千股背后资本是毫无底线的，它可以一直增发 一直合股 一直跌，最后你会发现哪怕涨百倍，你也回不了本！"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":293100978790568,"gmtCreate":1712577476473,"gmtModify":1712577486171,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LGVN\">$Longeveron Inc(LGVN)$ &nbsp;</a>两张图看蹊跷","listText":"<a href=\"https://laohu8.com/S/LGVN\">$Longeveron Inc(LGVN)$ &nbsp;</a>两张图看蹊跷","text":"$Longeveron Inc(LGVN)$ 两张图看蹊跷","images":[{"img":"https://static.tigerbbs.com/37442b679b0b3bdd7d42676b7b8997f7","width":"1080","height":"2400"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/293100978790568","isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},{"id":215259882102888,"gmtCreate":1693583496267,"gmtModify":1693583497869,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>机会都是跌出来的。我的策略很简单，每下跌2元，我扩大一倍投。 我在8.0买了1000 如果到了6，我买2000 如果到了4，我买4000 如果到了2，我买80000","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>机会都是跌出来的。我的策略很简单，每下跌2元，我扩大一倍投。 我在8.0买了1000 如果到了6，我买2000 如果到了4，我买4000 如果到了2，我买80000","text":"$Faraday Future(FFIE)$ 机会都是跌出来的。我的策略很简单，每下跌2元，我扩大一倍投。 我在8.0买了1000 如果到了6，我买2000 如果到了4，我买4000 如果到了2，我买80000","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/215259882102888","isVote":1,"tweetType":1,"viewCount":2261,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4134143716577510","authorId":"4134143716577510","name":"漏网的韭菜盒子","avatar":"https://static.tigerbbs.com/b739be9c8973f6c8c6c6a1923fcf0d26","crmLevel":4,"crmLevelSwitch":0},"content":"熊跌，我合股前也是这个思路0.25左右成本，还不是照样割韭菜，到2的时候，再合股一次，100和1","text":"熊跌，我合股前也是这个思路0.25左右成本，还不是照样割韭菜，到2的时候，再合股一次，100和1","html":"熊跌，我合股前也是这个思路0.25左右成本，还不是照样割韭菜，到2的时候，再合股一次，100和1"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":291672970248384,"gmtCreate":1712235182525,"gmtModify":1712235186843,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISA\">$WiSA Technologies(WISA)$ &nbsp;</a> 连续5日资金流入为正，必涨","listText":"<a href=\"https://laohu8.com/S/WISA\">$WiSA Technologies(WISA)$ &nbsp;</a> 连续5日资金流入为正，必涨","text":"$WiSA Technologies(WISA)$ 连续5日资金流入为正，必涨","images":[{"img":"https://static.tigerbbs.com/dadf58e625e91964b4f7296b9e4bcc6d","width":"1080","height":"2400"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/291672970248384","isVote":1,"tweetType":1,"viewCount":530,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":621496773,"gmtCreate":1672421060792,"gmtModify":1672421061790,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATNF\">$180 Life Sciences Corp(ATNF)$ &nbsp;</a>我赌这个公司会原地起跳","listText":"<a href=\"https://laohu8.com/S/ATNF\">$180 Life Sciences Corp(ATNF)$ &nbsp;</a>我赌这个公司会原地起跳","text":"$180 Life Sciences Corp(ATNF)$ 我赌这个公司会原地起跳","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/621496773","isVote":1,"tweetType":1,"viewCount":2140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":203889680150744,"gmtCreate":1690816043349,"gmtModify":1690817913727,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PBTS\">$宏桥高科(PBTS)$ &nbsp;</a>这王八蛋股票今天涨一点，明天必大跌。会一直跌到0.1以下再合并","listText":"<a href=\"https://laohu8.com/S/PBTS\">$宏桥高科(PBTS)$ &nbsp;</a>这王八蛋股票今天涨一点，明天必大跌。会一直跌到0.1以下再合并","text":"$宏桥高科(PBTS)$ 这王八蛋股票今天涨一点，明天必大跌。会一直跌到0.1以下再合并","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/203889680150744","isVote":1,"tweetType":1,"viewCount":882,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":623527901,"gmtCreate":1671541185904,"gmtModify":1671542025495,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a>最好是特斯拉再往下面跌，跌到130，跌一个月。那时候本大爷带50万杀进来","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a>最好是特斯拉再往下面跌，跌到130，跌一个月。那时候本大爷带50万杀进来","text":"$特斯拉(TSLA)$ 最好是特斯拉再往下面跌，跌到130，跌一个月。那时候本大爷带50万杀进来","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/623527901","isVote":1,"tweetType":1,"viewCount":10989,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3569968827736584","authorId":"3569968827736584","name":"电动汽车之王陈友谅","avatar":"https://static.tigerbbs.com/efab18c85c3be5514993af138c3a4f31","crmLevel":2,"crmLevelSwitch":0},"content":"50万冥币吗[贱笑][贱笑][贱笑] @陈友谅","text":"50万冥币吗[贱笑][贱笑][贱笑] @陈友谅","html":"50万冥币吗[贱笑][贱笑][贱笑] @陈友谅"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":623191109,"gmtCreate":1671102730602,"gmtModify":1671102772518,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ &nbsp;</a>资金在流入股价在跌。他妈的明显是空头打压","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ &nbsp;</a>资金在流入股价在跌。他妈的明显是空头打压","text":"$Faraday Future(FFIE)$ 资金在流入股价在跌。他妈的明显是空头打压","images":[{"img":"https://static.tigerbbs.com/8d5cc9c89515295ee5778df4a789ff4d","width":"1152","height":"2376"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/623191109","isVote":1,"tweetType":1,"viewCount":1785,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":215251515011192,"gmtCreate":1693581466990,"gmtModify":1693581467948,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a><v-v data-views=\"0\"></v-v>让子弹飞一会。我估摸得跌到5块左右","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a><v-v data-views=\"0\"></v-v>让子弹飞一会。我估摸得跌到5块左右","text":"$Faraday Future(FFIE)$ 让子弹飞一会。我估摸得跌到5块左右","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/215251515011192","isVote":1,"tweetType":1,"viewCount":1028,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575896644131469","authorId":"3575896644131469","name":"1直边走边看","avatar":"https://static.tigerbbs.com/6bd68883355b0208830081471bafd9a2","crmLevel":5,"crmLevelSwitch":0},"content":"到不了，好几次到7下不去了，今天还手率也下降很多","text":"到不了，好几次到7下不去了，今天还手率也下降很多","html":"到不了，好几次到7下不去了，今天还手率也下降很多"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":214527616757936,"gmtCreate":1693411787929,"gmtModify":1693411788842,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>这几日股价狂跌，但是资金大量流入。我是8.0入股。根据我的分析，到了大概5.0附近，会绝地反弹。","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$&nbsp;</a>这几日股价狂跌，但是资金大量流入。我是8.0入股。根据我的分析，到了大概5.0附近，会绝地反弹。","text":"$Faraday Future(FFIE)$ 这几日股价狂跌，但是资金大量流入。我是8.0入股。根据我的分析，到了大概5.0附近，会绝地反弹。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/214527616757936","isVote":1,"tweetType":1,"viewCount":1241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":627086146,"gmtCreate":1677768896485,"gmtModify":1677768897527,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$ &nbsp;</a>见好就收","listText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$ &nbsp;</a>见好就收","text":"$Exela Technologies, Inc.(XELA)$ 见好就收","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/627086146","isVote":1,"tweetType":1,"viewCount":1763,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":623254365,"gmtCreate":1671464819758,"gmtModify":1671464820594,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a>主力在不断的砸盘","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a>主力在不断的砸盘","text":"$特斯拉(TSLA)$ 主力在不断的砸盘","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/623254365","isVote":1,"tweetType":1,"viewCount":1453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":623377633,"gmtCreate":1671095458222,"gmtModify":1671095459172,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DIDIY\">$DiDi Global Inc.(DIDIY)$ &nbsp;</a>滴滴再跌，跌到一块6，我全给你买了","listText":"<a href=\"https://laohu8.com/S/DIDIY\">$DiDi Global Inc.(DIDIY)$ &nbsp;</a>滴滴再跌，跌到一块6，我全给你买了","text":"$DiDi Global Inc.(DIDIY)$ 滴滴再跌，跌到一块6，我全给你买了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/623377633","isVote":1,"tweetType":1,"viewCount":2369,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":300618599141688,"gmtCreate":1714412684257,"gmtModify":1714412688388,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/OPT/TSLA 20240517 210.0 CALL\">$TSLA 20240517 210.0 CALL$ &nbsp;</a>模拟盘12万美金一晚。爽一把也行","listText":"<a href=\"https://laohu8.com/OPT/TSLA 20240517 210.0 CALL\">$TSLA 20240517 210.0 CALL$ &nbsp;</a>模拟盘12万美金一晚。爽一把也行","text":"$TSLA 20240517 210.0 CALL$ 模拟盘12万美金一晚。爽一把也行","images":[{"img":"https://static.tigerbbs.com/92f4f1a3cfc0e930b5796f3e00c766b2","width":"906","height":"1406"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/300618599141688","isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":299545608568888,"gmtCreate":1714150648467,"gmtModify":1714150649827,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SISI\">$尚高生命科学(SISI)$ &nbsp;</a>要起来了","listText":"<a href=\"https://laohu8.com/S/SISI\">$尚高生命科学(SISI)$ &nbsp;</a>要起来了","text":"$尚高生命科学(SISI)$ 要起来了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/299545608568888","isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":189785366048792,"gmtCreate":1687359730302,"gmtModify":1687359732349,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ &nbsp;</a>做空特斯拉的时候到了","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ &nbsp;</a>做空特斯拉的时候到了","text":"$特斯拉(TSLA)$ 做空特斯拉的时候到了","images":[{"img":"https://static.tigerbbs.com/515498ceb34d5310370af943d03d96c6","width":"1152","height":"2327"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/189785366048792","isVote":1,"tweetType":1,"viewCount":914,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":621099961,"gmtCreate":1671720634753,"gmtModify":1671720635716,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a>我做空","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a>我做空","text":"$特斯拉(TSLA)$ 我做空","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/621099961","isVote":1,"tweetType":1,"viewCount":596,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":623866078,"gmtCreate":1671195032494,"gmtModify":1671195033521,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ &nbsp;</a>老贾让挺住啊","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ &nbsp;</a>老贾让挺住啊","text":"$Faraday Future(FFIE)$ 老贾让挺住啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/623866078","isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":659838473,"gmtCreate":1679933847992,"gmtModify":1679934546111,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FCNCA\">$第一公民银行股份(FCNCA)$ &nbsp;</a>先等子弹飞一会","listText":"<a href=\"https://laohu8.com/S/FCNCA\">$第一公民银行股份(FCNCA)$ &nbsp;</a>先等子弹飞一会","text":"$第一公民银行股份(FCNCA)$ 先等子弹飞一会","images":[{"img":"https://static.tigerbbs.com/d5d050c1491c480b904f19e77ba346ca","width":"1152","height":"2327"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/659838473","isVote":1,"tweetType":1,"viewCount":1199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":302941501505600,"gmtCreate":1714966408928,"gmtModify":1714966412688,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/53860\">$恒指瑞银六五熊Y.P(53860)$ &nbsp;</a> 易经之道。短期恒指有下跌，长期必涨","listText":"<a href=\"https://laohu8.com/S/53860\">$恒指瑞银六五熊Y.P(53860)$ &nbsp;</a> 易经之道。短期恒指有下跌，长期必涨","text":"$恒指瑞银六五熊Y.P(53860)$ 易经之道。短期恒指有下跌，长期必涨","images":[{"img":"https://static.tigerbbs.com/0e55b977d567c089546ff2cb88f9d88e","width":"906","height":"1406"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/302941501505600","isVote":1,"tweetType":1,"viewCount":65,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}